leadf
logo-loader
viewCo-Diagnostics

Full interview: Co-Diagnostics finalizes its own unique Coronavirus detection test

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the molecular diagnostics company has completed the principle design work for a genetic screening test to detect the deadly Wuhan coronavirus.

Egan says the test was developed using the Salt Lake City company’s PCR-based Co-Primer technology, which was recently represented at the International Plant & Animal Genome XXVIII in San Diego.

Quick facts: Co-Diagnostics

Price: 14.82 USD

NASDAQ:CODX
Market: NASDAQ
Market Cap: $416.19 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Co-Diagnostics named herein, including the promotion by the Company of Co-Diagnostics in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Co-Diagnostics to reach wider audience with FDA Emergency Use Authorization...

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the molecular diagnostics company's Logix Smart coronavirus test has obtained Emergency Use Authorization from the FDA to be used to diagnose SARS-CoV-2. Egan says the authorization confirms the quality and performance of the...

on 04/07/2020

2 min read